Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2016-03-16 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is a press release from Adocia announcing its annual financial results for 2015. It includes key financial highlights, a summary table of IFRS financial statements, management commentary, and operational updates. While it contains financial data, it is structured as an initial announcement (Earnings Release) rather than the full, audited Annual Report (10-K). It follows the standard format for an earnings release, providing a summary of performance before the full report is presented to shareholders at the AGM. FY 2015
2016-03-16 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces 'positive topline results' from a Phase 1b clinical study involving two pharmaceutical companies (Adocia and Lilly). It details specific clinical outcomes (blood glucose reduction percentages) and mentions safety results. This format—a concise announcement of key financial or operational milestones, often released via press wire—is characteristic of an Earnings Release (ER) or a general operational update. Since it is not a full annual report (10-K), a detailed interim report (IR), or a transcript (CT), and it focuses purely on announcing results rather than soliciting votes (DEF 14A/PSI) or detailing management changes (MANG), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal earnings reports to highlight key operational achievements like clinical trial success. It is not an RPA because it contains the substantive results, not just an announcement that a report is available.
2016-03-14 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces the positive principal results of a Phase 1b clinical study for a new insulin formulation (BioChaperone Lispro) developed by Adocia and licensed to Lilly. This type of announcement, detailing clinical trial outcomes and partnership updates, is typically classified as an Earnings Release (ER) if it pertains to periodic financial results highlights, or sometimes as Regulatory Filings (RNS) if it's a general corporate update. However, since it is a specific announcement of key clinical data and partnership progress, and not a full financial report (like 10-K or IR), it most closely aligns with the function of an Earnings Release (ER) which disseminates key performance/result highlights, even if the results are clinical rather than purely financial. Given the context of a press release announcing key study outcomes, ER is the most appropriate fit among the options, as it communicates significant, time-sensitive operational/development news. FY 2016
2016-03-14 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the company's 2015 revenue (chiffre d'affaires) and cash position as of December 31, 2015. It provides detailed financial figures, including revenue breakdowns and quarterly data, but it is presented as an announcement summarizing the results, not the full, comprehensive annual report (10-K) or a formal interim report (IR). This format, focusing on key financial highlights released to the public immediately, aligns best with the definition of an Earnings Release (ER). Although it contains more detail than a typical US earnings release, its primary function is the initial announcement of period-end financial results. FY 2015
2016-02-16 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and announces key financial metrics (revenue of EUR 36.9 million, cash position of EUR 72 million) for the full year 2015, dated February 16, 2016. This format—a brief announcement highlighting key figures immediately following the close of a fiscal period—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). It serves as the initial public disclosure of period results. FY 2015
2016-02-16 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces that the CEO will be presenting at an external industry event (2016 Leerink Global Healthcare Conference). It provides details about the presentation time and location, followed by boilerplate information about the company (Adocia) and contact details. This type of announcement, which informs the market about participation in an external conference rather than releasing mandatory periodic financial results (like 10-K or ER) or official voting outcomes, is best classified as a general regulatory announcement or a specific type of investor relations communication. Since there is no specific category for 'Conference Presentation Announcement' and it is not a formal financial report, it falls under the general regulatory/investor communication category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general, non-mandatory corporate news releases that don't fit other specific categories like DIV, ER, or CAP. It is not an Earnings Release (ER) as it is not reporting results, nor is it a Call Transcript (CT).
2016-02-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.